![1]()
News
Sotagliflozin use in T2D patients linked with posthospitalization benefits in analysis
June 23, 2021
The paper’s outcome measure may be a meaningful, patient-centered way of capturing disease burden, according to the authors.
News
AHA: Don’t delay COVID shot while CDC reviews myocarditis cases
June 17, 2021
It remains unclear if suspected myocarditis cases have any direct link to COVID vaccines, and the benefits of vaccination continue to ‘far exceed’ the risks, the AHA says.
News
First risk score to predict bleeding risk after TAVR
June 11, 2021
PREDICT-TAVR was developed and validated in two national registries in Europe and outperformed existing risk scores developed outside TAVR.
News
Medication in heart failure: Pro tips on therapy with the ‘four pillars of survival’
June 4, 2021
Consider multiple factors when titrating various medications.
![1]()
News
Subclinical myocarditis found in some athletes post COVID
June 2, 2021
A study that evaluated college athletes recently infected with COVID-19 with comprehensive cardiac testing, including MRI, found a small percentage had myocarditis despite being asymptomatic.
![1]()
News
New AHA/ASA guideline on secondary stroke prevention
May 27, 2021
Identifying the cause of a first stroke or transient ischemic attack is key to developing strategies to prevent repeat events, the AHA/ASA says in an updated clinical practice guideline.
News
AHA reassures myocarditis rare after COVID vaccination, benefits overwhelm risks
May 24, 2021
As CDC investigates rare, mostly mild cases of myocarditis in adolescents and young adults given the Pfizer or Moderna vaccine, AHA emphasizes their effectiveness and strong safety record.
![1]()
News
GALACTIC-HF: Novel drug most effective in sickest HFrEF patients
May 24, 2021
In GALACTIC-HF trial, the greatest relative benefit of omecamtiv mecarbil was in the sickest HFrEF patients.
![1]()
News
Sotagliflozin’s HFpEF benefit confirmed by new analyses
May 24, 2021
A meta-analysis of two pivotal trials for the SGLT1/2 inhibitor sotagliflozin prospectively documents a HFpEF benefit.
![1]()
News
FIDELIO-DKD: Finerenone cuts new-onset AFib in patients with type 2 diabetes and CKD
May 18, 2021
A prespecified, exploratory analysis from the FIDELIO-DKD trial showed that the nonsteroidal MRA finerenone significantly cut new-onset AFib.
